Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.
Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BMS-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed’s ibalizumab, can be the last hope for HIV+ patients who have no remaining treatment options. However, like any HIV drug, you have to combine with at least one more medication that can control your virus. If your doctor has told you that you have no more HIV medications left to bring your HIV viral load to undetectable, please email powertx@aol.com
More information on www.SalvageTherapies.org and https://www.thebody.com/Forums/AIDS/Nu…
BMS attachment inhibitor: https://clinicaltrials.gov/ct2/show/N…